Opium (Opioid) Addiction – Pipeline Review, H2 2019

“Global Markets Direct’s, ‘Opium (Opioid) Addiction – Pipeline Review, H2 2019’, provides an overview of the Opium (Opioid) Addiction pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Opium (Opioid) Addiction, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Opium (Opioid) Addiction and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.”

Scope


– The report provides a snapshot of the global therapeutic landscape of Opium (Opioid) Addiction

– The report reviews pipeline therapeutics for Opium (Opioid) Addiction by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Opium (Opioid) Addiction therapeutics and enlists all their major and minor projects

– The report assesses Opium (Opioid) Addiction therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Opium (Opioid) Addiction”

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Opium (Opioid) Addiction

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Opium (Opioid) Addiction pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

“Adapt Pharma Ltd

Adial Pharmaceuticals Inc

Alar Pharmaceuticals Inc

Amygdala Neurosciences Inc

Antheia Inc

Aoxing Pharmaceutical Company Inc

Aphios Corp

Aquilus Pharmaceuticals Inc

BioCorRx Inc

BioDelivery Sciences International Inc

BioXcel Therapeutics Inc

Cessation Therapeutics LLC

Delpor Inc

Emerald Bioscience Inc

Fab’entech SA

Indivior Plc

Insys Therapeutics Inc

iX Biopharma Ltd

Mind Medicine Inc

Nirsum Laboratories Inc

Omeros Corp

Opiant Pharmaceuticals Inc

Orexigen Therapeutics Inc

Orexo AB

Osmotica Pharmaceutical Corp

Pfizer Inc

Pharmazz Inc

Phoenix PharmaLabs Inc

Plumb Pharmaceuticals LLC

Serina Therapeutics Inc

Syntropharma Ltd

Titan Pharmaceuticals Inc

Trevena Inc

Vivera Pharmaceuticals Inc

Zynerba Pharmaceuticals Inc”

Table of Contents

Table of Contents

Table of Contents 2

Introduction 5

Opium (Opioid) Addiction Overview 6

Opium (Opioid) Addiction Therapeutics Development 7

Opium (Opioid) Addiction Therapeutics Assessment 16

Opium (Opioid) Addiction Companies Involved in Therapeutics Development 24

Opium (Opioid) Addiction Drug Profiles 34

Opium (Opioid) Addiction Dormant Projects 106

Opium (Opioid) Addiction Discontinued Products 107

Opium (Opioid) Addiction Product Development Milestones 108

Appendix 115

List of Tables

“List of Tables

Table 1: Number of Products under Development for Opium (Opioid) Addiction, H2 2019

Table 2: Number of Products under Development by Companies, H2 2019

Table 3: Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Table 4: Number of Products under Development by Universities/Institutes, H2 2019

Table 5: Products under Development by Companies, H2 2019

Table 6: Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Table 7: Products under Development by Universities/Institutes, H2 2019

Table 8: Number of Products by Stage and Target, H2 2019

Table 9: Number of Products by Stage and Mechanism of Action, H2 2019

Table 10: Number of Products by Stage and Route of Administration, H2 2019

Table 11: Number of Products by Stage and Molecule Type, H2 2019

Table 12: Opium (Opioid) Addiction – Pipeline by Adapt Pharma Ltd, H2 2019

Table 13: Opium (Opioid) Addiction – Pipeline by Adial Pharmaceuticals Inc, H2 2019

Table 14: Opium (Opioid) Addiction – Pipeline by Alar Pharmaceuticals Inc, H2 2019

Table 15: Opium (Opioid) Addiction – Pipeline by Amygdala Neurosciences Inc, H2 2019

Table 16: Opium (Opioid) Addiction – Pipeline by Antheia Inc, H2 2019

Table 17: Opium (Opioid) Addiction – Pipeline by Aoxing Pharmaceutical Company Inc, H2 2019

Table 18: Opium (Opioid) Addiction – Pipeline by Aphios Corp, H2 2019

Table 19: Opium (Opioid) Addiction – Pipeline by Aquilus Pharmaceuticals Inc, H2 2019

Table 20: Opium (Opioid) Addiction – Pipeline by BioCorRx Inc, H2 2019

Table 21: Opium (Opioid) Addiction – Pipeline by BioDelivery Sciences International Inc, H2 2019

Table 22: Opium (Opioid) Addiction – Pipeline by BioXcel Therapeutics Inc, H2 2019

Table 23: Opium (Opioid) Addiction – Pipeline by Cessation Therapeutics LLC, H2 2019

Table 24: Opium (Opioid) Addiction – Pipeline by Delpor Inc, H2 2019

Table 25: Opium (Opioid) Addiction – Pipeline by Emerald Bioscience Inc, H2 2019

Table 26: Opium (Opioid) Addiction – Pipeline by Fab’entech SA, H2 2019

Table 27: Opium (Opioid) Addiction – Pipeline by Indivior Plc, H2 2019

Table 28: Opium (Opioid) Addiction – Pipeline by Insys Therapeutics Inc, H2 2019

Table 29: Opium (Opioid) Addiction – Pipeline by iX Biopharma Ltd, H2 2019

Table 30: Opium (Opioid) Addiction – Pipeline by Mind Medicine Inc, H2 2019

Table 31: Opium (Opioid) Addiction – Pipeline by Nirsum Laboratories Inc, H2 2019

Table 32: Opium (Opioid) Addiction – Pipeline by Omeros Corp, H2 2019

Table 33: Opium (Opioid) Addiction – Pipeline by Opiant Pharmaceuticals Inc, H2 2019

Table 34: Opium (Opioid) Addiction – Pipeline by Orexigen Therapeutics Inc, H2 2019

Table 35: Opium (Opioid) Addiction – Pipeline by Orexo AB, H2 2019

Table 36: Opium (Opioid) Addiction – Pipeline by Osmotica Pharmaceutical Corp, H2 2019

Table 37: Opium (Opioid) Addiction – Pipeline by Pfizer Inc, H2 2019

Table 38: Opium (Opioid) Addiction – Pipeline by Pharmazz Inc, H2 2019

Table 39: Opium (Opioid) Addiction – Pipeline by Phoenix PharmaLabs Inc, H2 2019

Table 40: Opium (Opioid) Addiction – Pipeline by Plumb Pharmaceuticals LLC, H2 2019

Table 41: Opium (Opioid) Addiction – Pipeline by Serina Therapeutics Inc, H2 2019

Table 42: Opium (Opioid) Addiction – Pipeline by Syntropharma Ltd, H2 2019

Table 43: Opium (Opioid) Addiction – Pipeline by Titan Pharmaceuticals Inc, H2 2019

Table 44: Opium (Opioid) Addiction – Pipeline by Trevena Inc, H2 2019

Table 45: Opium (Opioid) Addiction – Pipeline by Vivera Pharmaceuticals Inc, H2 2019

Table 46: Opium (Opioid) Addiction – Pipeline by Zynerba Pharmaceuticals Inc, H2 2019

Table 47: Opium (Opioid) Addiction – Dormant Projects, H2 2019

Table 48: Opium (Opioid) Addiction – Dormant Projects, H2 2019 (Contd..1), H2 2019

Table 49: Opium (Opioid) Addiction – Discontinued Products, H2 2019”

List of Figures

“List of Figures

Figure 1: Number of Products under Development for Opium (Opioid) Addiction, H2 2019

Figure 2: Number of Products under Development by Companies, H2 2019

Figure 3: Number of Products under Development by Universities/Institutes, H2 2019

Figure 4: Number of Products by Top 10 Targets, H2 2019

Figure 5: Number of Products by Stage and Top 10 Targets, H2 2019

Figure 6: Number of Products by Top 10 Mechanism of Actions, H2 2019

Figure 7: Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019

Figure 8: Number of Products by Routes of Administration, H2 2019

Figure 9: Number of Products by Stage and Routes of Administration, H2 2019

Figure 10: Number of Products by Molecule Types, H2 2019

Figure 11: Number of Products by Stage and Molecule Types, H2 2019”

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports